Needham Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer maintains a Buy rating on Rhythm Pharmaceuticals (NASDAQ:RYTM) and raises the price target from $46 to $55.
July 25, 2024 | 11:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reaffirmed a Buy rating on Rhythm Pharmaceuticals and increased the price target from $46 to $55.
The reaffirmation of a Buy rating and the increase in the price target from $46 to $55 by a reputable analyst is likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100